KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TherapeuticsMD (TXMD) Equity Ratio (2016 - 2025)

TherapeuticsMD (TXMD) has disclosed Equity Ratio for 16 consecutive years, with 0.71 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Equity Ratio rose 3.6% year-over-year to 0.71, compared with a TTM value of 0.71 through Sep 2025, up 3.6%, and an annual FY2024 reading of 0.71, up 4.26% over the prior year.
  • Equity Ratio was 0.71 for Q3 2025 at TherapeuticsMD, roughly flat from 0.71 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.71 in Q3 2025 and bottomed at 1.05 in Q1 2022.
  • Average Equity Ratio over 5 years is 0.24, with a median of 0.57 recorded in 2023.
  • The sharpest move saw Equity Ratio plummeted 2561.13% in 2022, then surged 425.92% in 2023.
  • Year by year, Equity Ratio stood at 0.55 in 2021, then soared by 170.33% to 0.39 in 2022, then soared by 74.06% to 0.68 in 2023, then rose by 4.26% to 0.71 in 2024, then grew by 0.66% to 0.71 in 2025.
  • Business Quant data shows Equity Ratio for TXMD at 0.71 in Q3 2025, 0.71 in Q2 2025, and 0.7 in Q1 2025.